A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: The MOIO protocol study
Số trang: 10
Loại file: pdf
Dung lượng: 1.33 MB
Lượt xem: 9
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Immunotherapy (IO) has become a standard of care for treating various types of metastatic cancers and has significantly improved clinical outcome. With the exception of metastatic melanoma in complete response for which treatment can be stopped at 6 months, these treatments are currently administered until either disease pro‑ gression for some IO, 2 years for others, or unacceptable toxicity.
Nội dung trích xuất từ tài liệu:
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: The MOIO protocol study
Nội dung trích xuất từ tài liệu:
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: The MOIO protocol study
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Metastatic cancer Checkpoint inhibitors Health Economics Quality of lifeTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 172 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 94 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 44 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0